Compare NXGL & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXGL | SHPH |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.1M |
| IPO Year | 2019 | 2022 |
| Metric | NXGL | SHPH |
|---|---|---|
| Price | $3.94 | $5.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 595.0K | 37.6K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,421,000.00 | N/A |
| Revenue This Year | $38.23 | N/A |
| Revenue Next Year | $53.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.46 | N/A |
| 52 Week Low | $0.15 | $0.38 |
| 52 Week High | $214.40 | $8.88 |
| Indicator | NXGL | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 61.63 |
| Support Level | $3.12 | $2.92 |
| Resistance Level | $7.25 | $5.95 |
| Average True Range (ATR) | 0.92 | 0.44 |
| MACD | 0.32 | -0.02 |
| Stochastic Oscillator | 15.75 | 83.82 |
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.